Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
This study examined the antinociceptive (analgesic) efficacy of hydromorphone and hydromorphone-induced tolerance and regulation of mu-opioid receptor density. Initially s.c. hydromorphone's time of peak analgesic (tail-flick) effect (45 min) and ED50 using standard and cumulative dosing protocols (0.22 mg/kg, 0.37 mg/kg, respectively) were determined. The apparent analgesic efficacy (tau) of hydromorphone was then estimated using the operational model of agonism and the irreversible mu-opioid receptor antagonist clocinnamox. Mice were injected with clocinnamox (0.32-25.6 mg/kg, i.p.) and 24 h later, the analgesic potency of hydromorphone was determined. The tau value for hydromorphone was 35, which suggested that hydromorphone is a lower analgesic efficacy opioid agonist. To examine hydromorphone-induced tolerance, mice were continuously infused s.c. with hydromorphone (2.1-31.5 mg/kg/day) for 7 days and then morphine cumulative dose response studies were performed. Other groups of mice were injected with hydromorphone (2.2-22 mg/kg/day) once, or intermittently every 24 h for 7 days. Twenty-four hours after the last injection, mice were tested using morphine cumulative dosing studies. There was more tolerance with infusion treatments compared to intermittent treatment. When compared to higher analgesic efficacy opioids, hydromorphone infusions induced substantially more tolerance. Finally, the effect of chronic infusion (31.5 mg/kg/day) and 7 day intermittent (22 mg/kg/day) hydromorphone treatment on spinal cord mu-opioid receptor density was determined. Hydromorphone did not produce any change in mu-opioid receptor density following either treatment. These results support suggestions that analgesic efficacy is correlated with tolerance magnitude and regulation of mu-opioid receptors when opioid agonists are continuously administered. Taken together, these studies indicate that analgesic efficacy and treatment protocol are important in determining tolerance and regulation of mu-opioid receptors.
Kumar
Priyank
P
Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA.
Sunkaraneni
Soujanya
S
Sirohi
Sunil
S
Dighe
Shveta V
SV
Walker
Ellen A
EA
Yoburn
Byron C
BC
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D002934:Cinnamates / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004361:Drug Tolerance; D004091:Hydromorphone / Q000008:administration & dosage / Q000494:pharmacology*; D055104:Infusions, Subcutaneous; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D009022:Morphine Derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects*; D011930:Reaction Time; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000378:metabolism; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism
D000701:Analgesics, Opioid; D002934:Cinnamates; D009022:Morphine Derivatives; D009292:Narcotic Antagonists; C404943:Oprm protein, mouse; D017450:Receptors, Opioid, mu; C076806:clocinnamox; D004091:Hydromorphone
Eur J Pharmacol. 2007 Jun 1;563(1-3):92-101
17349996
J Pain Symptom Manage. 2005 May;29(5 Suppl):S57-66
15907647
Anal Biochem. 1976 May 7;72:248-54
942051
J Pain. 2005 Oct;6(10):662-72
16202959
J Pharmacol Exp Ther. 1990 Dec;255(3):1027-32
2175793
J Pharmacol Exp Ther. 1992 Sep;262(3):1051-6
1326622
Br J Pharmacol. 1985 Feb;84(2):561-71
3978322
J Pharmacol Exp Ther. 1992 Jul;262(1):1-9
1625189
Proc R Soc Lond B Biol Sci. 1983 Dec 22;220(1219):141-62
6141562
Mol Pharmacol. 2002 Dec;62(6):1464-70
12435815
Anesthesiology. 1995 May;82(5):1226-36
7741298
J Pharmacol Exp Ther. 1993 Apr;265(1):314-20
8386239
Mol Pharmacol. 2006 Nov;70(5):1575-84
16901982
Trends Pharmacol Sci. 1999 Jan;20(1):19-26
10101958
J Pharmacol Exp Ther. 2006 Mar;316(3):1195-201
16291875
Mol Pharmacol. 2005 Jan;67(1):280-7
15475572
Neuron. 1999 Aug;23(4):737-46
10482240
J Pharmacol Exp Ther. 2000 Mar;292(3):1127-34
10688632
J Biol Chem. 1996 Aug 9;271(32):19021-4
8702570
J Pharm Pharm Sci. 2007;10(4):504-18
18261371
Psychopharmacology (Berl). 2001 Mar 1;154(2):131-42
11314675
Eur J Pharmacol. 2004 Sep 13;498(1-3):87-96
15363980
Annu Rev Pharmacol Toxicol. 2002;42:349-79
11807176
J Neurosci. 2005 Aug 24;25(34):7847-57
16120787
Curr Opin Neurobiol. 2007 Oct;17(5):556-64
18068348
Life Sci. 1995;57(23):2113-25
7475964
J Pharmacol Exp Ther. 1987 May;241(2):374-8
3033213
Trends Pharmacol Sci. 2007 Aug;28(8):407-15
17629960
Mol Pharmacol. 1998 Mar;53(3):377-84
9495801
J Pharmacol Toxicol Methods. 1996 Aug;35(4):223-37
8823669
J Pharmacol Exp Ther. 1998 Jun;285(3):1197-206
9618423
J Biol Chem. 1998 May 29;273(22):13652-7
9593704
J Pharmacol Methods. 1990 May;23(3):225-37
2329803
J Pharmacol Exp Ther. 1989 Jul;250(1):1-8
2526212
Psychopharmacology (Berl). 1998 Mar;136(1):15-23
9537678
Pharmacol Biochem Behav. 1997 Sep;58(1):67-71
9264072
Pharmacol Biochem Behav. 2001 May-Jun;69(1-2):233-7
11420091